The global canine atopic dermatitis market size was USD 1,014.3 Million in 2020 and is expected to register a revenue CAGR of 8.8% during the forecast period. Steady revenue growth of the global canine atopic dermatitis market can be attributed to growing use of canine atopic dermatitis treatment products in the animal healthcare sector for treating different skin infections and allergies in dogs. Rise in the number of pets suffering from atopic dermatitis due to increasing pollution levels is also driving market growth.
Atopic dermatitis is a type of skin disorder or infection in animals with different symptoms such as scratching, itching, bad smell, hair loss, rough skin, and others. Canine atopic dermatitis can be most commonly observed in pet dog breeds such as German Shepherd, Labrador, Golden Retriever, and others.
Immunotherapy is a more well-known treatment for canine atopic dermatitis, as it is the treatment equipped for changing the immune system’s reaction to sensitivities instead of suppressing the immune system or dulling the clinical signs of the disease. Strict government rules and policies in various countries to restrict the use of human drugs on animals, rise in demand for pet insurance, and growing concern about pet health and hygiene among pet owners are boosting market revenue growth.
Products used for treating canine atopic dermatitis contain growth factors that assist in tissue recuperation and pain reduction, and also help in restoring proper skin health. Research on numerous drugs and therapy procedures is going on to get a better understanding and knowledge of what roles do different products play in the treatment of atopic dermatitis, which in turn, is expected to have a positive impact on growth of the global market.
Request a Sample@ https://qyresearchmedical.com/sample/118912
Market Dynamics:
Driver: Rising demand for canine atopic dermatitis products is a key revenue growth driving factor
Growing incidence of atopic dermatitis among pet dogs is increasing demand for canine atopic dermatitis products for treatment. Better product cost, emergence of new market players, and modern marketing endorsements are the factors expected to support canine atopic dermatitis market growth. Improvement in reimbursement policies, increasing research & development activities, and growing awareness among people regarding canine atopic dermatitis, along with increase in animal healthcare expenditure, are expected to drive growth of the global canine atopic dermatitis market.
Restraint: Use of off-level human drugs on animals and strict regulations for treatment of animals are key growth restraining factors
Use of off-label human drugs for animals in the animal healthcare sector is one of the major factors expected to restrain market growth. Complicated amalgamation processes, rules and regulations regarding treatment and therapy procedures to be used for animals, and high manufacturing cost of products are also hindering market growth. Moreover, complications and negative reactions after the use of several types of atopic dermatitis drugs may inhibit their use, which may hamper market growth over the forecast period.
Product Type Outlook:
Based on product type, the global canine atopic dermatitis market has been segmented into glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies, and others. Glucocorticoids segment accounted for largest revenue share in 2020 due to their growing use and less cost. Topical and oral glucocorticoids are the primary line of treatment for canine atopic dermatitis, and oral prednisone, prednisolone, and methylprednisolone are typically used for the treatment of intense flareups. Side effects of glucocorticoids are negligible in comparison to other products, which is increasing their adoption for treating atopic dermatitis in dogs.
Monoclonal antibodies segment is expected register a significantly high revenue CAGR over the forecast period. Monoclonal antibodies therapy is an advanced and effective treatment for atopic dermatitis.
Distribution Channel Outlook:
Based on distribution channel, the global canine atopic dermatitis market has been segmented into veterinary hospitals/clinics, retail, and e-commerce. Retail segment accounted for largest revenue share in 2020 due to availability of a large number of atopic dermatitis products in retail pharmacy stores as compared to other distribution channels. Adoption of digitalized frameworks in retail drug stores to reduce prescription errors and problems associated with it is expected to drive growth of the segment during the forecast period.
Veterinary hospitals/clinics segment is expected register a significantly high revenue CAGR over the forecast period. Rising preference of people for veterinary hospitals and clinics for treatment of their pets is increasing requirement of canine atopic dermatitis products, which is a major factor supporting market growth.
Mode of Administration Outlook:
Based on mode of administration, the global canine atopic dermatitis market has been segmented into topical, oral, and injectable. The oral segment revenue is growing due to its increasing usage and lesser cost. In addition, oral medications are more advantageous when compared to injectable and topical products, and pet owners can administer oral medications on their own. All these factors are expected to increase demand for oral medications and thus, drive growth of this segment.
The injectable segment revenue is expected to grow at a significantly high rate over the forecast period due to its efficacy and potency. Presently, veterinary doctors are recommending a blend of oral and injectable treatment for atopic dermatitis in dogs for better outcomes.
Regional Outlook:
Canine atopic dermatitis market in North America accounted for largest revenue share in 2020, which can be attributed to factors such as increase in the number of dogs suffering from atopic dermatitis and rising awareness about atopic dermatitis among people in the region. Moreover, presence of sophisticated technologies and well-developed animal healthcare infrastructure in the region are also expected to drive market growth in North America.
Canine atopic dermatitis market in Asia-Pacific is expected to register fastest revenue CAGR over the forecast period, owing to the presence of a large number of market players in the region and government initiatives for advancement in animal treatment. Moreover, APAC has a large pet population with skin disorders and infections, and subsequently, there is high demand for canine atopic dermatitis products in the region, which is driving growth of this regional market.
Competitive Landscape:
Competitive landscape of the global canine atopic dermatitis market is moderately fragmented with a number of key players operating on global and regional levels. Key players are engaged in product development and strategic alliances to expand their respective product portfolios and gain robust footing in the global market. Major players in the market include AB Science SA, Boehringer Ingelheim, Ceva Sante Animale, Dechra Veterinary Products, Elanco, Kindred Biosciences Inc., Merck and Co., Inc., Nextmune, Toray Industries Inc., Vetoquinol UK Ltd, and Zoetis.
Some Key Developments in the Market:
- In October 2020, Virbac received US FDA approval for its CYCLAVANCE (cyclosporine oral solution) USP MODIFIED to control atopic dermatitis in dogs weighing at least 4 lbs (1.8 kg).
- In September 2020, Zoetis received a variation to the terms of the marketing authorization for the veterinary medicinal product Cytopoint by the Committee for Medicinal Products for Veterinary Use (CVMP), in which the variation concerns adding a new therapeutic indication for the treatment of pruritus associated with allergic dermatitis in dogs.
Segments Covered in the Report:
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides an analysis of market trends in each sub-segment from 2018 to 2028. For this study, Reports and Data has segmented the canine atopic dermatitis market based on product type, distribution channel, mode of administration, and region:
Canine Atopic Dermatitis Market Report Scope
Segments covered By Product Type Outlook, Distribution Channel, Mode of Administration Outlook, Regional Outlook
By Product Type Outlook
Glucocorticoids
Antihistamines
Immunosuppressants
MAbs
Others
By Distribution Channel
Topical
Oral
Injectable
By Mode of Administration Outlook
Topical
Oral
Injectable
Regional scope
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118912/1500
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/